

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/48379 A1

(51) International Patent Classification⁷: C12N 15/85

(21) International Application Number: PCT/KR01/02178

(22) International Filing Date:
14 December 2001 (14.12.2001)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
2000/77279 15 December 2000 (15.12.2000) KR
2001/79227 14 December 2001 (14.12.2001) KR

(71) Applicant (for all designated States except US): PANGEN BIOTECH INC. [KR/KR]; 3rd Fl., R & D Center, KSBC 111-8, Iui-dong, Paldal-gu, Suwon, Kyungki-do 442-270 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Jeong Do [KR/KR]; #287-8 Seocheon-ri, Kiheung-eup, Yongin-city, Kyungki-do 449-906 (KR). HWANG, Hye-Yeon


[KR/KR]; Lotte Apt. 933-1202, Sanbon-dong, Kunpo, Kyungki-do 435-040 (KR). KIM, Dong-jun [KR/KR]; Saeotte Villa Building, #Ra, Rm 101, 388-4 Manpo-dong, Paldal-gu, Suwon, Kyungki-do 442-400 (KR). BAEK, Kwanghee [KR/KR]; 287-31, Jeki 1-dong, Dongdaemoon-gu, Seoul 130-061 (KR). YOON, Yeup [KR/KR]; Joongong Apt. 104-103, Joongang-dong 37, Kwacheon, Kyungki-do 427-010 (KR). YOON, Jaeseung [KR/KR]; 102-1502 Jungangheitzville, Jukjeon-Ri, Suji-Eup, Yongin City, Kyungki-do 449-845 (KR). LEESONG, Alex Inkeun [AU/AU]; 115/20 Albert Road, Strathfield, New South Wales 2135 (AU).

(74) Agent: YOUME PATENT AND LAW FIRM; Teheran Building, 825-33 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK,

[Continued on next page]

(54) Title: EXPRESSION VECTOR FOR ANIMAL CELL CONTAINING NUCLEAR MATRIX ATTACHMENT REGION FOR INTERFERON BETA



(57) Abstract: The present invention relates to mammalian expression vectors including nuclear matrix attachment region of human interferon β , and more particularly to pPGM-1, pPGM-2 and pPGM-3 including nuclear matrix attachment region of interferon β gene. Those expression vectors confer position independent expression of the introduced foreign gene, thus increasing the frequency of colonies which efficiently express the recombinant protein.

WO 02/48379 A1



SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**EXPRESSION VECTOR FOR ANIMAL CELL CONTAINING NUCLEAR
MATRIX ATTACHMENT REGION OF INTERFERON BETA**

BACKGROUND OF THE INVENTION

(a) Field of the Invention

5 The present invention relates to mammalian expression vectors including a nuclear matrix attachment region of interferon β gene, and more particularly to pPGM-1, pPGM-2, and pPGM-3.

(b) Description of the Related Art

 Various expression systems including microorganisms, plants,
10 yeasts, insect cells, mammalian cells, etc. have been used to express and obtain target proteins in large quantities to apply to medical and industrial uses. Microorganisms are the easiest systems to use, and microorganism expression systems suitable for various applications have been developed and are commonly used.

15 However, microorganism expression systems have some limitations. The most serious limitation is that since protein expression and modification mechanisms (glycosylation, phosphorylation, amidation) of microorganisms differ from those of mammalian cells, even if the same gene is expressed in a microorganism system, the structure or characteristics of expressed
20 proteins is not completely identical to the original protein. Therefore, production of recombinant proteins using microorganism expression

systems frequently expresses proteins that are inactivated because modification does not occur after synthesis, or that partially differ in modification or structure even if they are not significantly different in function. In addition, the recombinant protein production process using
5 microorganism expression systems should be accompanied by additional contaminant removal due to contamination of microorganisms, contamination of microorganism endotoxin, etc.

Meanwhile, mammalian expression systems, although they are the most suitable systems for expressing mammalian proteins, have not been
10 easily industrialized because recombinant protein expression efficiency is low and thus the unit cost of production is high, and the mammalian cell handling process is difficult. Presently used industrial mammalian cell lines include CHO (Chinese Hamster Ovary), BHK (Baby Hamster Kidney), myeloma, etc., and an expression vector including the gene of interest is
15 transfected into the mammalian cell line to express aimed foreign proteins.

Mammalian cells maintain various protein modification mechanisms including glycosylation, and protein obtainment and purification processes are easier when proteins are secreted to a culture medium. Most mammalian cells require complex additives such as serum protein, etc. in
20 the culture process, while CHO cells can be cultured in a medium without serum and protein, rendering it the most suitable host for expression of recombinant proteins. In addition, characteristics of CHO cells are well known due to their having been used in many studies, and they have

advantages of a high growth rate and that mass suspension culture is possible.

Generally, in order to express a transgene in a mammalian cell, a vector having a selection marker and a transgene are simultaneously transfected. Transfected cells are cultured and selected in a selection medium. However, expression frequency thereof is very low. One of the reasons is that these transgenes should be integrated in chromosomes of a host cell in mammalian cells contrary to the microorganism system. Additionally, even if stable transfectants are selected, the expression amount is difficult to predict. This is because gene integration positions differ according to cells, and expression aspects differ according to integration positions. Therefore, the copy number of transgenes in mammalian cells and the gene expression amount do not have an explicit correlation therebetween (Grindley et al., 1987, *Trends Genet.* 3, 16-22; Kucherlapati et al., 1984, *Crit. Rev. Biochem.* 16, 349-381; Palmiter et al., 1986, *Annu. Rev. Genet.* 20, 465-400). Gene expression in mammalian cells is mostly repressed by a nucleic acid base near the integration position, and thus stably integrated transgenes would often be expressed in a very low level (Eissenberg et al., 1991, *Trends Genet.* 7., 335-340; Palmiter et al., 1986, *Annu. Rev. Genet.* 20, 465-499).

Usability of nucleic acid factors for protecting transgene expression from position effects has been reported in many systems. As the nucleic acid factors, an insulator factor and a nuclear matrix attachment region

(MAR) or scaffold attachment region (SAR), etc. can be used. Although operation mechanisms thereof have not been clarified, when included in transgene constructs, they induce position independent gene expression and the expression amount is determined by the copy number of gene
5 (McKnight, R.A. et al., 1992, *Proc. Natl. Acad. US.* 89, 6943-6947).

Kalos et al. have combined the MAR factor of the human apolipoprotein B gene with a minimal promoter transgene construct and induced gene expression in mammalian cells to increase expression of the transcript by about 200 times (Kalos et al., 1995, *Mol. Cell. Biol.* 15, 198-
10 207). Similarly, it has been reported that the MAR factor of the chicken lysozyme A gene and the SAR factor of human interferon β , etc. confer position-independent transgene expression in vertebrates (Eissenberg et al., 1991, *Trends Genet.* 7, 335-340; Klehr et al., 1991, *Biochemistry* 30, 1264-1270). However, no attempt to apply the MAR/SAR factor to substantially
15 increase protein production in CHO cell lines has been reported, nor has industrial profit been identified.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a vector which confers increased foreign protein expression efficiency in
20 mammalian cells.

It is another object of the present invention to provide a vector for position independent expression of foreign proteins.

It is still another object of the present invention to provide a vector comprising a nuclear matrix attachment region of interferon β gene for increasing the frequency of foreign protein expression and the amount of foreign protein expressed in mammalian cells.

5 It is further object of the present invention to provide a vector comprising multiple cloning sites to facilitate the cloning of transgenes.

It is still further object of the present invention to provide a vector capable of expressing foreign proteins in mammalian cells.

In order to achieve these objects, the present invention provides
10 mammalian expression vectors comprising a nuclear matrix attachment region of interferon β gene, a promoter, and a transcription terminator.

The present invention also provides mammalian cells transfected with the expression vectors in which target genes are introduced.

The present invention also provides a method for production of
15 proteins comprising the steps of introducing transgenes into mammalian expression vectors and introducing the vector into mammalian cells to express proteins from the transgenes.

BRIEF DESCRIPTION OF THE DRAWINGS

20 Fig. 1 shows a structure of a vector constructed by modifying a pSV- β -gal vector in order to construct the expression vector of the present invention.

Fig. 2 shows the β -gal staining method which demonstrates the

increase in the frequency of positive cells by nuclear matrix attachment region of interferon β gene.

Fig. 3 shows frequency of positive cell lines that express β -gal when amplifying introduced genes by adding MTX

5 Fig. 4 shows β -gal expression frequency and expression amount in a G418 selection medium.

Fig. 5 shows β -gal expression frequency and expression amount in a DHFR selection medium.

10 Fig. 6 shows β -gal expression frequency and expression amount in the presence of a CMV promoter.

Fig. 7 shows the structure of the pPGM-1 expression vector of the present invention.

Fig. 8 shows the map of the pPGM-2 expression vector of the present invention and a base sequence of multiple cloning sites.

15 Fig. 9 shows the map of the pPGM-3 expression vector of the present invention.

Fig. 10 shows results of analyzing expression titer of a human growth hormone expression cell line prepared using pPGM-1, by Western Blot.

20 Fig. 11 shows results of analyzing expression titer of an interferon β expression cell line prepared using pPGM-1, by Western Blot.

DETAILED DESCRIPTION AND THE PREFERRED EMBODIMENTS

The present inventors invented optimum expression vectors for overcoming position-specific expression inhibition effect (hereinafter referred to as "position effect") and improving gene expression amounts in transgene expression in mammalian expression systems.

The mammalian expression vector of the present invention further added a useful base sequence to the existing expression vectors. The useful base sequence protects transgene expression from position effects of the host cell chromosome, and increases transgene expression in CHO (Chinese hamster ovary) or BHK (Baby hamster kidney) cells, etc., commonly used as commercial mammalian cells. The useful base sequence is preferably the nuclear matrix attachment region (MAR) or scaffold attachment region (SAR).

The MAR/SAR factor is preferably selected from a group consisting of chicken lysozyme 5' MAR (Phi-Van, L. and Stratling, W.H., 1996, *Biochemistry* 35, 10735-10742, Gene bank #: X98408), chicken α globin 5'MAR (Kraevskii, V.A. et al., 1992, *Mol. Biol.* 26, 672-678, Gene bank #: X64113), CHO DHFR intron MAR (Kas, E. and Chasin, L.A., 1987, *J. Mol. Biol.* 198, 677-692, Gene bank #: X06654), human HRRT intron MAR (Sykes, R.C. et al., 1988, *Mol. Gen. Genet.* 212, 301-309, Gene bank #: X07690), human CSP-B gene flanking SAR (Hanson, R.D. and Ley, T.J., Gene bank #: M62716), and human interferon β gene flanking SAR (Mielke, C. et al., 1990, *Biochemistry* 29, 7475-7485, Gene bank #:

M83137).

Influences of the MAR/SAR factor on transgene expression were analyzed by integrating 6 kinds of MAR/SAR factors into pSV- β -gal/ver I or pSV- β -gal/ver II and examining expression aspects of β -gal genes.

5 Six kinds of MAR/SAR factors were respectively integrated into upstream of a promoter of pSV- β -gal/ver I or pSV- β -gal/ver II to complete a test vector. The test vector was introduced to CHO DG44 cells to prepare a transfected cell line, and β -gal expression frequency and expression amount were measured.

10 The recombinant vector pSB β /I including interferon β MAR factor was compared with pSV- β -gal as a control. The number of colonies increased by about 3 times in a G418 medium, and frequency of positive cell lines expressing β -gal increased to 71% compared to 35% of the control, thus the number of positive cell lines increased by 6 times.

15 In addition, when pSV β /I transfected cell lines were selected in a DHFR selection medium, the number of positive colonies that were produced in initial selection medium not including nucleoside increased by 10 times. When MTX was added to a culture medium to induce transgene amplification, the β -gal positive colony rate of the pSV β /I transfected cell
20 line was 90% or more of total colonies, and the number of positive cells increased to about 7 times as much as the control pSV- β -gal (Fig. 3).

Accordingly, the interferon β MAR factor of the present invention

increases expression efficiency of transgenes and selection marker genes to largely enhance growth of transfected cell lines in selection medium, and shortens periods required for selecting transfected cell lines in selection mediums.

5 The present invention also provides mammalian expression vectors including a nuclear matrix attachment region of interferon β at a upstream of promoter 5'. The mammalian expression vectors are preferably pPGM-1, pPGM-2, and pPGM-3. The promoter is preferably selected from a group consisting of SV40 promoter, CMV (cytomegalovirus) promoter, and
10 MMTV (Mouse Mammary Tumor Virus) promoter.

 The pPGM-1 vector contains a 5409bp including a nuclear matrix attachment region of the human interferon β gene, a SV40 virus promoter, and multiple cloning sites (MCS), and it can express various genes by integrating transgenes in multiple cloning sites. Multiple cloning sites
15 include *HindIII*, *NheI*, *NotI*, and *XhoI* restriction sites. The base sequence of the pPGM-1 vector is listed as SEQ ID NO: 1 in the sequence listing program, and major factors included in the vector and their positions are shown in Table 1 and Fig. 7. The pPGM-1 vector was deposited with the Korean Culture Collection of Microorganisms under deposition no. KCCM
20 10232.

Table 1

Sequence No.	Functions
1-413	Initial promoter and enhancer of SV40 virus
414-448	Multiple cloning sites (MCS)

449-584	Small T antigen of SV40 virus
1194-2054	β -lactamase: Amp ^R gene
3225-5397	Nuclear matrix attachment region of interferon β gene

The pPGM-2 vector, which modifies multiple cloning sites of the pPGM-1 vector, includes a nuclear matrix attachment region of the interferon β gene, a SV40 promoter, and multiple cloning sites. The base sequence of the pPGM-2 is listed as SEQ ID NO: 2, and the structure of the vector is shown in Fig. 8 and Table 2. The multiple cloning sites of the pPGM-2 vector include *NheI*, *PmeI*, *AflIII*, *BamHI*, *BstXI*, *EcoRV*, *NotI*, *XhoI*, *XbaI*, *ApaI*, *PmeI*, and *MluI* restriction sites. The pPGM-2 vector was deposited with the Korean Culture Collection of Microorganisms under deposition no. KCCM 10338.

Table 2

Sequence No.	Functions
1-413	SV40 promoter
426-445	T7 promoter
446-579	Multiple cloning sites (MCS)
1331-2191	β -LACTAMASE: Amp ^R gene
3361-5534	Nuclear Matrix Attachment Region of interferon β gene

The pPGM-3 vector which substitutes the SV40 promoter of the pPGM-1 vector with the CMV (Cytomegalovirus) derived promoter consists of 5601 bp. The base sequence thereof was shown as SEQ ID NO: 3, and the structure is shown in Fig. 9 and Table 3. The pPGM-3 vector was deposited with the Korean Culture Collection of Microorganisms under KCCM 10339.

Table 3

Sequence No.	Functions
1-611	SV40 promoter
612-640	Multiple cloning sites (MCS)
1396-2246	β -lactamase:Amp ^R gene
3417-5589	Nuclear Matrix Attachment Region of interferon β gene

The pPGM-1 vector, pPGM-2 vector, and pPGM-3 vector of the present invention are superior to common vectors in number of positive cells expressing transgenes, frequency, and expression amount. Therefore, the pPGM-1 vector, pPGM-2 vector, and pPGM-3 vector of the present invention can be used for expressing and producing transgenes in mammalian cells, and they can produce recombinant proteins such as enzyme and cytokine.

In addition, the present invention introduces a transgene into a vector including a nuclear matrix region of the interferon β gene, and introduces it into a mammalian cell to provide a transfected cell line. The transfected cell line is selected by culturing in a medium to which a selection marker or MTX is added. A transgene is a gene encoding all kinds of proteins capable of being expressed as recombinant proteins. Representative examples include insulin, cytokine (interleukin, tumor necrosis factor, interferon, colony stimulation factor, chemokine, etc.), erythropoietin, etc. The transfected cell line can be produced by a common method.

In addition, the present invention provides a method of producing proteins comprising : introducing a transgene into a vector including a

nuclear matrix attachment region of the interferon β gene, and introducing the vector into a mammalian cell to express proteins from a transgene. The vector is preferably selected from a group consisting of pPGM-1 (KCCM 10232), pPGM-2 (KCCM 10338), and pPGM-3 (KCCM 10339).
5 The mammalian cell can be any mammalian-derived cell, and it is preferably CHO (Chinese hamster ovary).

As described above, the pPGM-1 vector, pPGM-2 vector, and pPGM-3 vector of the present invention improve repression of transgene expression caused by surrounding bases and increase expression. In
10 addition, the expression vector of the present invention can be effectively applied to mass production of industrially useful proteins, and it can produce recombinant proteins having the same structure and functions as original proteins of higher animals.

The present invention will be explained in further detail with
15 reference to the following Examples and Comparative Examples. However, these are to illustrate the present invention and the present invention is not limited to them.

Example 1: Cloning of MAR or SAR factor

Genomic DNA was isolated from human G-2 cells using a Wizard
20 Genomic DNA purification kit (Promega, U.S.A.). 10 μ g of DNA were cut with *Clal*, *SmaI*, *XbaI*, and *XhoI* restriction enzymes to use in the PCR process. DNA to be used in PCR was separated and purified from a CHO chicken cell line and a chicken embryo by a similar method.

200 ng of the isolated genomic nucleic acid was used as a template, and 25 pmole of each primer, 0.5 mM of dNTP, and ExTaq polymerase (Takara Shuzo Co., Japan) were added to carry out PCR. The base sequence of primer used for each MAR/SAR factor and size of DNA
 5 fragment obtained by PCR are as shown in Table 4. PCR was carried out using a GeneAmp PCR system 9600 (Perkin – Elmer Corp. U.S.A.), and PCR conditions are as shown in Table 5.

Table 4

MAR/SAR factor	Primer	SEQ ID NO:	Size
Chicken lysozyme 5'MAR	5'-GGA TCC ATA ATA TAA CTG TA-3'	4	1668 bp
	5'-AAG CTT AAA AGA TTG AAG CA-3'	5	
Chicken phi α globin 5'MAR	5'-AAG CTT TTA ACC AAC AAA AA-3'	6	619 bp
	5'-CTG CAG ACC TAA CCT GTC AC-3'	7	
CHO DHFR intron MAR	5'-TAT ACG TGA ATA GTT TTT CT-3'	8	549 bp
	5'-GAG TTG GAA CTG AGA AGT TC-3'	9	
Human HPRT intron MAR	5'-AAG CTT GGT CAA GA TGG TG-3'	10	580 bp
	5'-GCT GGG CGT GGT GGT GCC TG-3'	11	
Human CSP-8 gene SAR	5'-GGA TCC GAT TCT CCT TGA TG-3'	12	1233 bp
	5'-GAA TTC AAA CAA CTC AAT AG-3'	13	
Human interferon β SAR	5'-GAA TTC AGC AAG GTC GCC AC-3'	14	2174 bp
	5'-TTG TAT CAA CTT TCT ACA AT-3'	15	

10

Table 5

Step	Conditions	Cycle
1	94°C, 2 min	1
2	94°C, 40 sec; 65°C, 40 sec; 72°C, 40 sec	2-31
3	72°C, 10 min	32

Fragments of chicken lysozyme 5' MAR (Gene bank #: X98408, hereinafter referred to as "lyso MAR"), chicken phi α globin 5' MAR (Gene

bank #: X64113, hereinafter referred to as "phi-a MAR"), CHO DHFR intron MAR (Gene bank #: X06654, hereinafter referred to as "DHFR MAR"), human HPRT intron MAR (Gene bank #: X07690, hereinafter referred to as "HPRT MAR"), human CSP-B gene flanking SAR (Gene bank #: M62716, hereinafter referred to as "CSP-B MAR"), and human interferon β gene flanking SAR (Gene bank #: M83137, hereinafter referred to as "interferon β MAR") were separated by the above-explained method.

The PCR product was subcloned in pT7blue (R) (Novagene, U.S.A.) or a pCR 2.1 (Invitrogen, U.S.A.) vector. HPRT MAR, DHFR MAR, and lyso MAR were subcloned in a pT7blue (R) vector, and phi-a MAR, CSP-B MAR, and interferon β MAR were subcloned in PCR 2.1.

Example 2: Construction of pSV- β -gal/ver I and pSV- β -gal/ver II vectors

In order to effectively clone multiple MAR/SAR factors subcloned in the pT7blue (R) or pCR 2.1 vector at upstream of a SV40 promoter of a pSV- β -gal (hereinafter referred to as 'pSV β ') vector, modified pSV- β -gal/ver I and PSV- β -gal/ver II vectors were constructed (Fig. 1).

(1) Construction of pSV- β -gal/ver I

PCR was carried out with pSV β as a template with primers of SEQ ID NO: 16 and SEQ ID NO: 17 to obtain a fragment including the SV40 promoter. The fragment was cut with *SpeI* and *HindIII* enzymes, and a

443 bp of DNA fragment including SV40 was purified with a GeneClean III kit (Bio 101, U.S.A). It was subcloned in a opened pBluescript SK (+) vector (Stratagene, U.S.A.) with *SpeI* and *HindIII* enzymes to construct pBS/SV40 I.

5 The pBS/SV40 I was digested with *SalI* and *HindIII* enzymes to separate a 1240 bp DNA fragment, and it was subcloned in pSV β treated with the same enzymes to complete a pSV- β -gal/ver vector.

(2) Construction of pSB- β -gal/ver II vector

A pSV β was cut with *EcoRI* and *HindIII* to obtain a 420 bp fragment
10 by the above-explained method, and the fragment was inserted into a pBluescript SK (+) vector opened with the same enzymes to construct a pSV- β -gal/ver II vector.

Example 3: Construction of a vector including MAR factor and 15 β -gal gene

MAR factors were separated from pT7blue(R)/HPRT MAR, bT7blue(R)/DHFR MAR, pT7blue(R)/lyso MAR, pCR 2.1/phi-a MAR, pCR 2.1/CSP-B MAR, and pCR 2.1/interferon β MAR, and cloned in pSV β /I or pSV β /II.

20 In a pSV β /I, phi-a MAR and HPRT MAR (human HPRT intron MAR) were subcloned using *SpeI/SmaI*, and interferon β MAR and lyso MAR were subcloned using *Apal/SpeI*. Constructed vectors were pSV- β -

gal/phi-a MAR , pSV- β -gal/HPRT MAR, pSV- β -gal/interferon β MAR
(hereinafter referred to as 'pSV β /I'), and pSV- β -gal/lyso MAR.

Additionally, DHFR MAR and CSP-B MAR were subcloned in pSV-
 β -gal/ver II at *Bam*HI/*Xba* I restriction site. Constructed vectors were
5 pSV- β -gal/DHFR MAR and pSV- β -gal/CSP-B MAR respectively.

Example 4: Construction of pCMV β and pCMV β /I

A *Spe*I-*Xho*I fragment including a MAR factor was deleted from a
pSV β /I vector and the vector was self-ligated. After cleavage by *Apa*I and
10 *Hind*III, a CMV promoter fragment was inserted to construct a pCMV β
vector. The CMV promoter was amplified by PCR with primers of SEQ ID
NO: 18 and SEQ ID NO:19 in a pcDNA3.1 vector. The sequences of SEQ
ID NO: 18 and SEQ ID NO:19 include a *Apa*I or *Hind*III restriction site.

Also, a pSV β I vector was digested with *Apa*I and *Hind*III restriction
15 enzymes and a CMV promoter fragment was integrated therein to construct
a pCMV β /I vector.

Namely, pCMV β is a vector without the MAR factor, and pCMV β /I
is a vector having the MAR factor.

20 Example 5: Measurement of gene expression of pSV β and pSV β /I

(1) Transfection

A CHO cell line DG44 deficient of the DHFR gene was cultured in a MEM- α medium (α -Minimum Essential Medium, Gibco BRL) to which 10% serum (fetal bovine serum) was added. 2×10^5 cells were inoculated on a 60 mm plate together with 3 ml of medium and cultured in 5% CO₂ incubator at 37°C overnight, until transfection occurred.

Transfection was carried out by a liposome method. A pSV2Neo or pDCH1P vector having selection maker gene was co-transfected with each test vector in a mole ratio of 100:1, and a pSV β vector was used as a control to perform the same experiment. 2 μ g of each vector were mixed with lipid surfactant, DOSPER (BOEHRINGER Mannheim, German) and serum-free MEM- α medium and reacted at room temperature for 45 minutes, it was added to a rinsed cell together with a medium to culture for 5 hours, and then the reaction liquid was removed. Culture was carried out in MEM- α medium including 10% FBS and G418 (500 μ g/ml) for 2 weeks in order to select the transfected cell line using a Neo gene, and culture was carried out in MEM- α medium not including a nucleoside for 2 weeks in order to select a DHFR gene, and β -gal expression was analyzed.

(2) Measurement of frequency of β -gal expression positive cell line

Positive cells expressing β -gal were selected.

Cells cultured on a 100 mm plate were treated with a fixing agent (2% formaldehyde and 0.2% glutaraldehyde) at 4 °C for 10 minutes. They

were washed with 1X PBS twice, and X-gal (1 mg/ml) was added to react them at 37 °C.

A β -gal expression cell can be easily identified because it decomposes X-gal and shows a blue color. Positive cells were separated with a trypsin-EDTA solution, and the number of cells was measured with a hematocytometer.

Fig. 2 is a photo of cells treated with X-gal after being transfected with pSV β or pSV β /I in order to identify β -gal expression cells. (a) shows cells transfected with pSV β , and (b) shows cells transfected with pSV β /I. A positive cell line showing a blue color of pSV β /I transfected cell line is remarkable in the upper plate photo.

After transfection, the transfected cell line was selected using a Neo gene or a DHFR gene, and the number of positive cells expressing β -gal were measured.

Table 6 shows the number of β -gal positive cells of DG44/PSV β or DG44/PSV β /I selected using the Neo selection factor. Table 7 shows the number of β -gal positive cells of DG44/pSV β or DG44/pSV β /I selected using the DHFR selection factor.

Table 6

	Total cell number	Positive Cell number	Negative Cell number	Positive Cell Frequency (%)
DG44/pSV β	222	145	77	34.68
DG44/pSV β /I	659	191	468	71.02

Table 7

	Total Cell number	Positive Cell number	Negative Cell number	Positive Cell Frequency (%)
DG44/pSV β	120	105	15	12.50
DG44/pSV β /I	350	200	150	42.86

The total number of colonies and frequency of positive colonies increased, and the number of positive colonies remarkably increased, when
 5 the transfected cell lines were selected by culturing in selection maker existing media.

In addition, the transfected cell line (DG44/pSV β , DG44/pSB β /I) was adapted to a MTX-added medium to induce gene amplification. The β -gal expression frequency of the transfected cell line adapted to MTX 10
 10 nM and 50 nM was measured. Fig. 3 is a graph measuring activity of the β -gal of MTX-adapted transfected cell line. 90% or more of the DG44/PSV β /I transfected cell line selected in MTX expressed β -gal, and produced 7 times as many positive colonies as the control (pSV β).

Accordingly, the interferon β MAR factor further enhanced
 15 expression activity of the SV40 promoter to increase frequency of positive cell lines by 6-10 times. A common transfected cell line preparation process requires that transfected cell lines should be selected from a selection medium for a very long period. However, it is expected that the MAR factor will sharply shorten the period of time required for development
 20 of transfected cell lines. In addition, the MAR factor affects expression of

selected genes as well as target genes to largely enhance growth of recombinant cell lines in the selection medium.

(3) β -gal activities of DG44/pSV β and DG44/pSV β /I

β -gal activity of the same cell as used to measure frequency of the

5 β -gal expression positive cell line was measured.

A transfected cell line was cultured for 48 hours and washed with 1X PBS twice. 1 ml of STE (0.1M NaCl, 10 mM Tris-Cl (pH 8.0) and 1 mM EDTA (pH 8.0) solution were added thereto and it was put on ice. Cells were scraped with a scraper, moved to an eppendorf tube, centrifuged at 10 4 °C at 14000 rpm for 40 seconds to remove supernatant, and 100 μ l of 0.25 M Tris-Cl (pH 7.5) was added to mix with the cells. A process for freezing under liquid nitrogen and immediately melting at 37 °C was repeated 5 times. The pulverized cells were centrifuged at 4 °C at 12000 rpm for 10 minutes and supernatant was moved to a new tube to analyze it.

15 30 μ l of cell extracts, 3 μ l of 100 X magnesium solution (0.1 M $MgCl_2$, 4.5 M β -mercaptoethanol), 66 μ l of 1 X ONPG (4 ml/ml in 0.1 M sodium phosphate (pH 7.5)), and 201 μ l of 0.1 M sodium phosphate (pH 7.5) were mixed well, and reacted at 37 °C until the color changed to yellow. After adding 500 μ l of 1M Na_2CO_3 , absorbance was measured at 20 420 nm.

The protein amount in solution was measured by the bicinchoninic acid (BCA) method (Smith et al., 1985, Anal. Biochem. 150, 76-85).

Fig. 4 is a graph measuring β -gal activity of DG44/pSV β or DG44/pSV β /I selected with the Neo selection maker. Fig. 5 is a graph measuring β -gal activity of DG44/pSV β or DG44/pSV β /I selected with the DHFR selection maker.

5 When the MAR factor existed in the expression vector, β -gal activities increased 7.5 times (Fig. 4) and 32 times (Fig. 5), respectively. This indicates that, considering the frequency of positive cells, expressed β -gal protein activity per positive cell substantially increased.

10 **Example 6: Measurement of β -gal expression of pCMV β and pCMV β /I**

Each of pCMB β and pCMV β /I was transfected into DG44 by the same method as in Example 5, and number of β -gal positive cell lines and activities were measured.

15 Fig. 6 is a graph showing β -gal activities of DG44/pCMV β and DG44/pCMV β /I, and Table 8 shows the number of β -gal positive cells of DG44/pCMV β and DG44/pCMV β /I.

Table 8

	Total Cell number	Positive Cell number	Negative Cell number	Positive Cell Frequency (%)
DG44/pCMV β	180	147	33	18.33
DG44/pCMV β /I	326	79	247	75.77

20 The MAR factor increased frequency of positive cell lines from

18.33% to 75.77% even under a CMV promoter, and it increased the total number of colonies by about 1.8 times and the number of positive colonies by about 7.5 times. Therefore, it is suggested that the effects of interferon β MAR factor are not limited to the SV40 promoter, and that the MAR factor of the present invention can be used in various promoter including SV40, CMV promoter, and other promoters.

Example 7: Construction pPGM-1 vector

A β -gal site was deleted from a pSV β /I vector and multiple cloning sites (MCS) were inserted to construct a pPGM-1 vector with the genetic map of Fig. 7.

A *Hind*III – *Bam*HI fragment including a β -gal gene was removed from a pSV β /I vector, and 160 bp of a *Hind*III/*Bam*HI fragment of pMSG (KCCM 10202) was inserted. The pPGM-1 vector was deposited with the Korean Culture Collection of Microorganisms and assigned deposit No. KCCM 10232.

Example 8: Construction of pPGM-2 vector

A pPGM-1 vector was inserted with multiple cloning sites to construct a pPGM-2 vector.

A *Hind*III – *Bam*HI fragment of a pSV β vector was substituted with a pMSG (KCCM 10202) derived corresponding fragment, and the vector was opened with an *Eco*RI enzyme to integrate an interferon MAR factor. It was treated with *Nhe*I and *Xho*I enzymes and a fragment including

multiple cloning sites and a T7 promoter was ligated. The fragment was prepared using a PCR primer (Sequence No. 20 and Sequence No. 21) comprising *AvrII* and *SaII* restriction site.

Fig. 8 shows the map of the pPGM-2 vector and base sequence of multiple cloning sites, and the vector was deposited with the Korean Culture Collection of Microorganisms and assigned deposit No. KCCM 10338.

Example 9: Construction of pPGM-3 vector

A *HindIII* – *BamHI* fragment of pSV β -1 vector was substituted with a pMSG (KCCM 10202) derived corresponding fragment. The vector was digested with *EcoRI* and *NheI* to delete a promoter and substitute it with a CMV promoter, and it was opened with an *EcoRI* enzyme to ligate an interferon MAR factor. The structure of the constructed pPGM-3 vector is shown in Fig. 9, and its deposit No. is KCCM 10339.

Example 10: Production of recombinant protein using pPGM-1 vector

The pPGM-1 vector was digested with *NheI* and *XhoI* enzymes and integrated genes were ligated. The genes were cDNA encoding human growth hormone (Gene Bank #: E01424) or human interferon β (Gene Bank #: V00534).

The constructed expression vector was transfected into CHO DG44 cells and a high expression transfected cell line was selected while increasing the concentration of MTX added to a medium. Expression titer was measured by Western Blot, as shown in Figs. 10 and 11.

1.08 X 10⁵ cells were put in a 12-well plate and cultured for 48 hours, and the medium was pooled to carry out Western Blot. Lane 1 is 25 ng of positive control protein, and lanes 2 – 5 are culture solutions derived from different colonies selected. The expression rate for human growth
5 hormones was measured at about 20 µg/ml/day, and the expression rate for interferon β was approximately 15 µg/ml/day.

WHAT IS CLAIMED IS:

1. A mammalian expression vector comprising:
 - (a) a nuclear matrix attachment region of interferon β gene;
 - (b) a promoter; and
 - 5 (c) a transcription terminator.
2. The mammalian expression vector according to Claim 1, wherein the promoter is selected from a group consisting of SV40 promoter, CMV (cytomegalovirus) promoter, and MMTV (mouse mammary tumor virus) promoter.
- 10 3. The mammalian expression vector according to Claim 1, wherein the mammalian expression vector is pPGM-1 KCCM 10232.
4. The mammalian expression vector according to Claim 1, wherein the mammalian expression vector is pPGM-2 KCCM 10338.
5. The mammalian expression vector according to Claim 1, wherein
15 the mammalian expression vector is pPGM-3 KCCM 10339.
6. A cell transfected with a mammalian expression vector of Claim 1 in which target gene was inserted.
7. The cell according to Claim 6, wherein the mammalian expression vector is selected from a group consisting of pPGM-1 (KCCM 10232),
20 pPGM-2 (KCCM 10338), and pPGM-3 (KCCM 10339).
8. The cell according to Claim 6, wherein the cell is a mammalian cell or a cell derived from a mammalian organism.
9. The cell according to Claim 6, wherein the cell is derived from

CHO (Chinese hamster ovary) cell line.

10. A method of producing recombinant protein comprising:

introducing a transgene into the mammalian expression vector of

Claim 1; and


5 transfecting mammalian cells with the expression vector in order to
express protein from the transgene.

11. The method according to Claim 10, wherein the mammalian
expression vector is selected from a group consisting of pPGM-1 (KCCM
10232), pPGM-2 (KCCM 10338), and pPGM-3 (KCCM 10339).

10


1/11

FIG. 1




2/11

FIG. 2




3/11

FIG. 3




4/11

FIG. 4




5/11

FIG. 5




6/11

FIG. 6



7/11

FIG. 7




AAGCTTG CTAGCGGCCG CAGATCTGTT AACTCGAG

HindIII *NheI* *NotI* *XhoI*

8/11

FIG. 8



5' ... TAATA CGACT CACTA TAGGG AGACC CAAGC TGGCT AGCGT T TAAA CTAA GCTTG

T7 Promoter Nhe I Pme I Afl II


GTACC GAGCT CCGAT CCACT AGTCC AGTGT GGTGG AATTC TGCAG A TATC CAGCA
 BamHI BstXI EcoRV

CAGTG GCGGC CGCTC GAGTC TAGAG GGCCC GTTTA AACAC GCGT... 3'

BstXI NotI XhoI XbaI ApaI PmeI MluI

9/11

FIG. 9




GCTAGCGGC CGCAGATCTG TTAAGTCGAG

Restriction sites are indicated below the sequence:

- NheI (under GCTAGCGGC)
- NotI (under CGCAGATCTG)
- XhoI (under TTAAGTCGAG)


10/11

FIG. 10



11/11

FIG. 11



Sequence Listing

<110> PAN-GEN BIOTECH LABORATORIES INC.

<120> EXPRESSION VECTOR FOR ANIMAL CELL CONTAINING NUCLEAR MATRIX
ATTACHMENT REGION OF INTERFERON BETA

<150> KR 10-2000-77279
<151> 2000-12-15

<150> KR 10-2001-79227
<151> 2001-12-14

<160> 21

<170> KopatentIn 1.71

<210> 1
<211> 5409
<212> DNA
<213> Artificial Sequence

<220>
<223> pPGM-1 vector

<220>
<221> promoter
<222> (1)..(419)
<223> SV40 virus

<220>
<221> gene
<222> (449)..(584)
<223> small T antigen of SV40 virus

<220>
<221> gene
<222> (1194)..(2054)
<223> beta-lactamase

<220>

<221> gene

<222> (3225)..(5397)

<223> interferon beta MAR

<400> 1

```

gcgcagcacc atggcctgaa ataacctctg aaagaggaac ttggttaggt accttctgag      60
gcggaaagaa ccagctgtgg aatgtgtgtc agttaggggtg tggaaagtcc ccaggctccc      120
cagcaggcag aagtatgcaa agcatgcac tcaattagtc agcaaccagg tgtggaaagt      180
ccccaggctc ccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca      240
tagtcccgcc cctaactccg cccatcccg ccctaactcc gcccagttcc gccattctc      300
cgccccatgg ctgactaatt ttttttatt atgcagaggc cgaggccgccc tcggcctctg      360
agctattcca gaagtagtga ggaggctttt ttggaggcct aggccttttc aaaaagcttg      420
ctagcggccg cagatctgtt aactcgagaa cttgtttatt gcagcttata atggttacaa      480
ataaagcaat agcatcaca atttcacaaa taaagcattt ttttactgc attctagtgt      540
tggtttgtcc aaactcatca atgtatctta tcatgtctgg atcggcatgc aagctggcac      600
tggccgtcgt ttacaacgt cgtgactggg aaaacctgg cgttacccaa cttaatcgcc      660
ttgcagcaca tcccccttc gccagctggc gtaatagcga agaggccgc accgatcgcc      720
cttcccaaca gttgcgcagc ctgaatggcg aatggcgcc gatgcggtat tttctcctta      780
cgcatctgtg cggtatctca caccgcatat ggtgcactct cagtacaatc tgctctgatg      840
ccgcatagtt aagccagccc cgacaccgc caacaccgc tgacgcgccc tgacgggctt      900
gtctgtcccc ggcacccgt tacagacaag ctgtgaccgt ctccgggagc tgcattgtgc      960

```

agagggttttc accgtcatca ccgaaacgcg cgagacgaaa gggcctcgtg atacgcctat	1020
ttttataggt taatgtcatg ataataatgg tttcttagac gtcagggtggc acttttcggg	1080
gaaatgtgcg cggaaccctt atttgtttat ttttctaaat acattcaaatt atgtatccgc	1140
tcattgagaca ataaccctga taaatgcttc aataatattg aaaaaggaag agtatgagta	1200
ttcaacattt ccgtgtcggc cttattccct tttttcggc attttgcctt cctgtttttg	1260
ctcaccacaga aacgtgtgtg aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg	1320
gttacatcga actggatctc aacagcggta agatccttga gagttttcgc ccgaagaac	1380
gttttccaat gatgagcact tttaaagttc tgctatgtgg cgcggtatta tcccgtattg	1440
acgccgggca agagcaactc ggtcgcgcga tacactattc tcagaatgac ttggttgagt	1500
actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa ttatgcagtg	1560
ctgccataac catgagtgat aacactgcgg ccaacttact tctgacaacg atcggaggac	1620
cgaaggagct aaccgctttt ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt	1680
gggaaccgga gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgcctgtag	1740
caatggcaac aacgttgccg aaactattaa ctggcgaact acttactcta gcttccggc	1800
aacaattaat agactggatg gaggcggata aagttgcagg accacttctg cgtcggccc	1860
ttccggctgg ctggtttatt gctgataaat ctggagccgg tgagcgtggg tctcgcggta	1920
tcattgcagc actggggcca gatggtaagc cctcccgat cgtagttatc tacacgacgg	1980
ggagtcaggc aactatggat gaacgaaata gacagatcgc tgagataggt gcctcactga	2040
ttaagcattg gtaactgtca gaccaagttt actcatatat acttttagatt gatttaaaac	2100
ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc atgacaaaa	2160

tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag atcaaaggat 2220

cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc 2280

taccagcggg ggtttgtttg ccgatcaag agctaccaac tctttttccg aaggtaactg 2340

gcttcagcag agcgcagata ccaataactg ttcttctagt gtagccgtag ttaggccacc 2400

acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaactctg ttaccagtgg 2460

ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga tagttaccgg 2520

ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcgaa 2580

cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg 2640

aaggagagaa ggcggacagg tatccggtaa gcggcagggt cggaacagga gagcgcacga 2700

gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcggggtt cgccacctct 2760

gacttgagcg tcgatttttg tgatgctcgt caggggggag gagcctatgg aaaaacgcca 2820

gcaacgcggc ctttttacgg ttctggcct tttgctggcc ttttgtcac atgttctttc 2880

ctgcgttatc ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataccg 2940

ctcgccgcag ccgaacgacc gagcgacgag agtcagttag cgaggaagcg gaagagcgcc 3000

caatacgcaa accgcctctc ccgcgcgtt ggccgattca ttaatgcagc tggcacgaca 3060

ggtttcccg a ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt tagctcactc 3120

attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt ggaattgtga 3180

gcggataaca atttcacaca ggaaacagct atgacatgat tacgaattca gcaaggtcgc 3240

cacgcacaag atcaatatta acaatcagtc atctctcttt agcaataaaa aggtgaaaaa 3300

ttacatttta aaaatgacac catagacgat gtatgaaaat aatctacttg gaaataaatc 3360

taggcaaaga agtgcaagac tgttacccag aaaacttaca aattgtaaat gagaggtag 3420

tgaagattta aatgaatgaa gatctaaata aacttataaa ttgtgagaga aattaatgaa 3480

tgtctaagtt aatgcagaaa cggagagaca tactatatc atgaactaaa agacttaata 3540

ttgtgaaggt atactttctt ttcacataaa ttgtagtca atatgttcac cccaaaaaag 3600

ctgtttgtta acttgtcaac ctcatctcaa aatgtatata gaaagcccaa agacaataac 3660

aaaaatattc ttgtagaaca aaatgggaaa gaatgttoca ctaaataatca agatttagag 3720

caaagcatga gatgtgtggg gatagacagt gaggtgata aaatagagta gagctcagaa 3780

acagacccat tgatatatgt aagtgcctta tgaaaaaaat atggcatttt acaatgggaa 3840

aatgatgatc tttttctttt ttagaaaaac agggaaatat atttatatgt aaaaaataaa 3900

agggaaacca tatgtcatc catacacaca aaaaaattcc agtgaattat aagtctaaat 3960

ggagaaggca aaactttaaa tcttttagaa aataatatag aagcatgcc tcatgacttc 4020

agtgtagaga aaaatttctt atgactcaaa gtcctaacca caaagaaaag attgttaatt 4080

agattgcatg aatattaaga cttattttta aaattaataaa accattaaga aaagtcaggc 4140

catagaatga cagaaaatat ttgcaacacc ccagtaaaga gaattgtaat atgcagatta 4200

taaaaagaag tcttacaat cagtaaaaaa taaaactaga caaaaatttg aacagatgaa 4260

agagaaactc taaataatca ttacacatga gaaactcaat ctcagaaatc agagaactat 4320

cattgcatat acactaaatt agagaaatat taaaaggcta agtaacatct gtggcaatat 4380

tgatggtata taaccttgat atgatgtgat gagaacagta ctttacccca tgggcttcct 4440

ccccaaacc ttacccagat ataatcatg acaaatatac tttaaaaacc attaccctat 4500

atctaaccag tactcctcaa aactgtcaag gtcacaaaa ataagaaaag tctgaggaaac 4560

tgtcaaaact aagaggaacc caaggagaca tgagaattat atgtaatgtg gcattctgaa 4620
 tgagatccca gaacagaaaa agaacagtag ctaaaaaact aatgaaatat aaataaagtt 4680
 tgaactttag ttttttttaa aaaagagtag cattaacacg gcaaagtcatt tttcatattt 4740
 ttcttgaaca ttaagtacaa gtctataatt aaaaattttt taaatgtagt ctggaacatt 4800
 gccagaaaca gaagtacagc agctatctgt gctgtcgcct aactatccat agctgattgg 4860
 tctaaatga gatacatcaa cgctcctcca tgttttttgt tttcttttta aatgaaaaac 4920
 tttatttttt aagaggagtt tcaggttcat agcaaaattg agaggaaggt acattcaagc 4980
 tgaggaagtt ttcctctatt cctagtttac tgagagattg catcatgaat ggggtgttaa 5040
 ttttgtcaaa tgctttttct gtgtctatca atatgaccgt gtgattttct tctttaacct 5100
 gttgatggga caaattacgt taattgattt tcaaacgttg aaccaccctt acatatctgg 5160
 aataaattct acttggttgt ggtgtataatt ttttgataca ttcttggatt ctttttgcta 5220
 atattttgtt gaaaatgttt gtatctttgt tcatgagaga tattggtctg ttgttttctt 5280
 ttcttgaat gtcattttct agttccggtt ttaaggtaat gctggcctag ttgaatgatt 5340
 taggaagtat tccctctgct tctgtcttct gaaagagatt gtagaaagtt gatacaaaag 5400
 ccgaattcg 5409

<210> 2
 <211> 5546
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> pPGM-2 vector

<220>

<221> promoter

<222> (1)..(419)

<223> SV40 virus

<220>

<221> primer_bind

<222> (426)..(445)

<223> T7 promoter

<220>

<221> gene

<222> (1331)..(2191)

<223> beta-lactamase gene

<220>

<221> gene

<222> (3361)..(5534)

<223> Interferon beta MAR elemen

<400> 2

gcgcagcacc atggcctgaa ataacctctg aaagaggaac ttggtaggt accttctgag	60
gcggaaagaa ccagctgtgg aatgtgtgtc agttagggtg tggaaagtcc ccaggctccc	120
cagcaggcag aagtatgcaa agcatgcac tcaattagtc agcaaccagg tgtggaaagt	180
ccccaggctc ccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca	240
tagtcccgcc cctaactccg cccatccgc ccctaactcc gccagttcc gccattctc	300
cgcccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc tcggcctctg	360
agctattcca gaagtagtga ggaggctttt ttggaggcct aggcctttgc aaaaagcttg	420

ctaggtaata cgactcacta tagggagacc caagctggct agcgtttaaa cttagcttg 480

gtaccgagct cggatccact agtccagtgt ggtggaattc tgcagatata cagcacagt 540

gcggccgctc gagtctagag ggcccgttta aacacgcgtg tcgagaactt gtttattgca 600

gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatTTTT 660

tcactgcatt ctagtgtggt tttgtccaaa ctcatcaatg tatcttatca tgtctggatc 720

ggcatgcaag ctggcactgg ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt 780

tacccaactt aatcgccctg cagcacatcc ccctttcgcc agctggcgta atagcgaaga 840

ggcccgacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat ggcgcctgat 900

gcggtatttt ctccctacgc atctgtgcgg tatttcacac cgcataatgg gcactctcag 960

tacaatctgc tctgatgccg catagttaag ccagccccga caccgcgcaa caccgctga 1020

cgcgcctga cgggcttgct tgetcccgcc atccgcttac agacaagctg tgaccgtctc 1080

cgggagctgc atgtgtcaga ggttttcacc gtcacacacc aaacgcgcga gacgaaaggg 1140

cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt cttagacgtc 1200

aggtggcact tttcggggaa atgtgcgcgg aaccctattt tgtttatttt tctaaataca 1260

ttcaaataatg tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa 1320

aaggaagagt atgagtattc aacatttccg tgtcgcctt attccctttt ttgcggcatt 1380

ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca 1440

gttgggtgca cgagtgggtt acatcgaaact ggatctcaac agcggtaaga tccttgagag 1500

ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagtctctg tatgtggcgc 1560

ggtattatcc cgtattgacg ccgggcaaga gcaactcggc cgccgcatac actattctca 1620

gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt	1680
aagagaatta tgcagtgtg ccataacat gaggataac actgcggcca acttacttct	1740
gacaacgac ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt	1800
aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga	1860
caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact	1920
tactctagct tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc	1980
acttctgcgc tcggcccttc cggtctggctg gtttattgct gataaatctg gagccggtga	2040
gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt	2100
agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgtga	2160
gatagggtgcc tcaactgatta agcattggta actgtcagac caagtttact catatatact	2220
ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga tcctttttga	2280
taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccg	2340
agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct gctgcttgca	2400
aacaaaaaaa ccaccgctac cagcgggtgt ttgtttgccg gatcaagagc taccaactct	2460
ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgttc ttctagtga	2520
gccgtagtta ggccaccact tcaagaactc ttagcacog cctacatacc tcgctctgct	2580
aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggaactc	2640
aagacgatag ttaccggata aggcgcagcg gtcgggctga acgggggggt cgtgcacaca	2700
gccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga	2760
aagcgccacg cttcccgaa ggaagaaaggc ggacaggtat ccggtaagcg gcagggtcgg	2820

aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggatatctt atagtcctgt	2880
cggttttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag	2940
cctatggaaa aacgccagca acgcggcctt ttacgggttc ctggcctttt gctggccttt	3000
tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta ttaccgcctt	3060
tgagtgaagt gataccgctc gccgcagccg aacgaccgag cgcagcaggt cagtgaagca	3120
ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc cgattcatta	3180
atgcagctgg cagcagaggt ttcccgaact gaaagcgggc agtgagcgca acgcaattaa	3240
tgtgagttag ctcaactcatt aggcacccca ggctttacac tttatgcttc cggctcgtat	3300
gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg acatgattac	3360
gaattcagca aggtcgccac gcacaagatc aatattaaca atcagtcata tctcttttagc	3420
aataaaaagg tgaaaaatta cattttaaaa atgacaccat agacgatgta tgaaaataat	3480
ctacttgga ataatctag gcaaagaagt gcaagactgt taccagaaa acttacaat	3540
tgtaaatgag aggttagtga agatttaaat gaatgaagt ctaaataaac ttataaattg	3600
tgagagaaat taatgaatgt ctaagttaat gcagaaacgg agagacatac tatattcatg	3660
aactaaaaga cttaatatg tgaaggtata ctttcttttc acataaattt gtagtcaata	3720
tggtcacccc aaaaagctg ttgtttaact tgcaacctc atttcaaat gtatatagaa	3780
agcccaaaga caatacaaaa aatattcttg tagaacaaa tgggaaagaa tgttcacta	3840
aatatcaaga ttagagcaa agcatgagat gtgtggggat agacagtga gctgataaaa	3900
tagagtagag ctcagaaaca gaccattga tatatgaag tgacctatga aaaaatatg	3960
gcattttaca atgggaaaaat gatgatcttt ttctttttta gaaaaacag gaaatatatt	4020

tatatgtaaa aaataaaag gacccatat gtcataccat acacacaaaa aaattccagt	4080
gaattataag tctaaatgga gaaggcaaaa ctttaaatct tttagaaaat aatatagaag	4140
catgccatca tgacttcagt gtagagaaaa atttcttatg actcaaagtc ctaaccacaa	4200
agaaaagatt gttaattaga ttgcatgaat attaagactt atttttaaaa ttaaaaaacc	4260
attaagaaaa gtcaggccat agaatgacag aaaatatattg caacacccca gtaaagagaa	4320
ttgtaatatg cagattataa aaagaagtct tacaatcag taaaaataa aactagacaa	4380
aaatttgaac agatgaaaga gaaactctaa ataatcatta cacatgagaa actcaatctc	4440
agaaatcaga gaactatcat tgcataata ctaaattaga gaaatattaa aaggctaagt	4500
aacatctgtg gcaatattga tggatatataa ccttgatatg atgtgatgag aacagtactt	4560
taccccatgg gcttcctccc caaacctta ccccgatata aatcatgaca aatatacttt	4620
aaaaaccatt accctatata taaccagtac tcctcaaaac tgtcaaggtc atcaaaaata	4680
agaaaagtct gaggaactgt caaaactaag aggaacccaa ggagacatga gaattatatg	4740
taatgtggca ttctgaatga gatccagaa cagaaaaaga acagtagcta aaaaactaat	4800
gaaatataaa taaagtttga acttttagttt tttttaaaaa agagtagcat taacacggca	4860
aagtcatttt catatttttc ttgaacatta agtacaagtc tataattaaa aatttttta	4920
atgtagtctg gaacattgcc agaaacagaa gtacagcagc tatctgtgct gtcgcctaac	4980
tatccatagc tgattggtct aaaatgagat acatcaacgc tcctccatgt tttttgtttt	5040
ctttttaaat gaaaaacttt attttttaag aggagtttca ggttcatagc aaaattgaga	5100
ggaaggtaca ttcaagctga ggaagtttct ctctattcct agtttactga gagattgcat	5160
catgaatggg tgttaaattt tgtcaaatgc tttttctgtg tctatcaata tgaccgtgtg	5220

```

atcttcttct ttaacctgtt gatgggacaa attacgttaa ttgattttca aacgttgaac      5280
cacccttaca tatctggaat aaattctact tggttgtggt gtatattttt tgatacattc      5340
ttggattctt ttgctaata ttttgttgaa aatgtttgta tctttgttca tgagagatat      5400
tggctctgtg ttttcttttc ttgtaatgtc attttctagt tccgggatta aggtaatgct      5460
ggcctagttg aatgatttag gaagtattcc ctctgcttct gtcttctgaa agagattgta      5520
gaaagttgat acaaaagccg aattcg                                           5546

```

```

<210>      3
<211>      5601
<212>      DNA
<213>      Artificial Sequence

```

```

<220>
<223>      pPGM-3 vector

```

```

<220>
<221>      promoter
<222>      (1)..(611)
<223>      CMV promoter

```

```

<220>
<221>      gene
<222>      (1386)..(2246)
<223>      beta-lactamase gene

```

```

<220>
<221>      gene
<222>      (3417)..(5589)
<223>      Interferon beta MAR element

```

<400> 3

gaattcacta gtgattaggc cccgttgaca ttgattattg actagttatt aatagtaatc	60
aattacgggg tcattagtgc atagcccata tatggagttc cgcgttacat aacttacggt	120
aaatggcccc cctggctgac cgcccaacga ccccgccca ttgacgtcaa taatgacgta	180
tgttcccata gtaacgcaa tagggacttt ccattgacgt caatgggtgg agtatttacg	240
gtaaactgcc cacttgccag tacatcaagt gtatcatatg ccaagtacgc cccctattga	300
cgtcaatgac ggtaaatggc ccgcctggca ttatgccag tacatgacct tatgggactt	360
tcctacttgg cagtacatct acgtattagt catcgtatt accatggtga tgcggttttg	420
gcagtacatc aatgggcgtg gatagcgggt tgactcacgg ggatttccaa gtctccaccc	480
cattgacgtc aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg	540
taacaactcc gccccattga cgcaaatggg cggtaggcgt gtacgggtgg aggtctatat	600
aagcagagct cgctagcggc cgcagatctg ttaactcgag aacttggtta ttgcagctta	660
taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttact	720
gcattctagt tgtggtttgt ccaaactcat caatgtatct tatcatgtct ggatcggcat	780
gcaagctggc actggcgtc gttttacaac gtcgtgactg ggaaaaccct ggcgttaccc	840
aacttaatcg ccttgacga catccccctt tcgccagctg gcgtaatagc gaagaggccc	900
gcaccgatcg cccttcccaa cagttgcgca gcctgaatgg cgaatggcgc ctgatgcggt	960
atcttctcct tacgcatctg tgcggtatct cacaccgcat atggtgcact ctcatgaca	1020
tctgctctga tgcgcgatag ttaagccagc cccgacaccc gccaacaccc gctgacgcgc	1080
cctgacgggc ttgtctgctc ccggcatccg cttacagaca agctgtgacc gtctccggga	1140
gctgcatgtg tcagaggttt tcaccgtcat caccgaaacg cgcgagacga aagggcctcg	1200

tgatacgctt atttttatag gttaatgtca tgataataat ggtttcttag acgtcagggtg	1260
gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa	1320
atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga	1380
agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc	1440
ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg	1500
gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc	1560
gccccgaaga acgtttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat	1620
tatcccgat tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg	1680
acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag	1740
aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa	1800
cgatcggagg accgaaggag ctaaccgctt ttttgacaa catgggggat catgtaactc	1860
gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca	1920
cgatgcctgt agcaatggca acaacgttgc gcaactatt aactggcgaa ctacttactc	1980
tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc	2040
tgcgctcggc ccttcgggtt ggctggttta ttgctgataa atctggagcc ggtgagcgtg	2100
ggtctcggcg tatcattgca gcaactgggc cagatggtaa gccctcccgt atcgtagtta	2160
tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag	2220
gtgcctcact gattaagcat tggttaactgt cagaccaagt ttactcatat atactttaga	2280
ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc	2340
tcatgaccaa aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa	2400

agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc ttgcaaacia	2460
aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca actcttttct	2520
cgaaggtaac tggttcagc agagcgaga taccaaatac tgttcttcta gtgtagccgt	2580
agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaattc	2640
tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac	2700
gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc acacagccca	2760
gcttgagcg aacgacctac accgaactga gatacctaca gcgtgagcta tgagaaagcg	2820
ccacgcttcc cgaagggaga aaggcgga cgtatccggt aagcggcagg gtcggaacag	2880
gagagcgac gaggagcct ccagggggaa acgcctggt tctttatagt cctgtcgggt	2940
tctgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg cggagcctat	3000
ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg cttttgctc	3060
acatgttctt tcttgcgtta tccctgatt ctgtggataa ccgtattacc gcctttgagt	3120
gagctgatac cgctcgccgc agccgaacga ccgagcgag cgagtcagt agcgaggag	3180
cggaagagcg cccaatacgc aaaccgctc tccccgcgcg ttggccgatt cattaatgca	3240
gctggcacga caggtttccc gactggaaag cgggcagtga gcgcaacgca attaatgtga	3300
gttagctcac tcattaggca ccccaggctt tacactttat gcttcgggt cgtatgttgt	3360
gtggaattgt gagcggataa caatttcaca caggaaacag ctatgacatg attacgaatt	3420
cagcaaggtc gccacgcaca agatcaatat taacaatcag tcattctctt ttagcaataa	3480
aaagggtgaa aattacattt taaaaatgac accatagacg atgtatgaaa ataactact	3540
tggaaataaa tctaggcaaa gaagtgcag actgttacc agaaaactta caaattgtaa	3600

atgagagggt agtgaagatt taaatgaatg aagatctaaa taaacttata aattgtgaga	3660
gaaattaatg aatgtctaag ttaatgcaga aacggagaga catactatat tcatgaacta	3720
aaagacttaa tattgtgaag gtatactttc ttttcacata aattttagt caatatgttc	3780
acccccaaaa agctgtttgt taacttgtea acctcatttc aaaatgtata tagaaagccc	3840
aaagacaata acaaaaatat tcttgtagaa caaaatggga aagaatgttc cactaaatat	3900
caagatttag agcaaagcat gagatgtgtg gggatagaca gtgaggctga taaaatagag	3960
tagagctcag aaacagagcc attgatatat gtaagtgacc tatgaaaaaa atatggcatt	4020
ttacaatggg aaaatgatga tctttttctt ttttagaaaa acagggaaat atatttatat	4080
gtaaaaata aaaggaacc catatgtcat accatacaca caaaaaaatt ccagtgaatt	4140
ataagtctaa atggagaagg caaaacttta aatcttttag aaaataatat agaagcatgc	4200
catcatgact tcagtgtaga gaaaaatttc ttatgactca aagtcctaac cacaaagaaa	4260
agattgttaa ttagattgca tgaatattaa gacttatttt taaaattaaa aaaccattaa	4320
gaaaagtcag gccatagaat gacagaaaat atttgcaaca ccccgataaa gagaattgta	4380
atatgcagat tataaaaaga agtcttacia atcagtaaaa aataaaacta gacaaaaatt	4440
tgaacagatg aaagagaaac tctaaataat cattacacat gagaaactca atctcagaaa	4500
tcagagaact atcattgcat atacactaaa ttagagaaat attaaaaggc taagtaacat	4560
ctgtggcaat attgatggtg tataaccttg atatgatgtg atgagaacag tactttaccc	4620
catgggcttc ctccccaaac ccttaccoca gtataaatca tgacaaatat actttaaaaa	4680
ccattaccct atatctaacc agtactctc aaaactgtca aggtcatcaa aaataagaaa	4740
agtctgagga actgtcaaaa ctaaggaggaa cccaaggaga catgagaatt atatgtaatg	4800

tggcattctg aatgagatcc cagaacagaa aaagaacagt agctaaaaaa ctaatgaaat 4860
 ataaataaag tttgaacttt agtttttttt aaaaaagagt agcattaaca cggcaaagtc 4920
 attttcatat ttttcttgaa cattaagtac aagtctataa ttaaaaattt tttaaagtga 4980
 gtctggaaca ttgccagaaa cagaagtaca gcagctatct gtgctgtcgc ctaactatcc 5040
 atagctgatt ggtctaaaat gagatacatc aacgctctc catgtttttt gttttctttt 5100
 taaatgaaaa actttatttt ttaagaggag ttccagggtc atagcaaaat tgagaggaag 5160
 gtacattcaa gctgaggaag ttttctctta ttcctagttt actgagagat tgcacatga 5220
 atgggtgtta aattttgtca aatgcttttt ctgtgtctat caatatgacc gtgtgatattt 5280
 cttctttaac ctgttgatgg gacaaattac gttaattgat tttcaaactg tgaaccaccc 5340
 ttacatatct ggaataaatt ctacttggtt gtgggtgtata ttttttgata cattcttgga 5400
 ttctttttgc taatattttg ttgaaaatgt ttgtatcttt gttcatgaga gatattggtc 5460
 tgttgtttcc ttttcttgta atgtcatttt ctagtccgg tattaaggta atgctggcct 5520
 agttgaatga tttaggaagt attccctctg cttctgtctt ctgaaagaga ttgtagaaag 5580
 ttgatacaaa agccgaattc g 5601

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for MAR of chicken lysozyme A

<400> 4

ggatccataa tataactgta

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for MAR of chicken lysozyme A

<400> .5

aagcttaaaa gattgaagca

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for chicken phi alpha-globin 5' MAR

<400> 6

aagcttttaa ccaacaaaaa

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer for chicken phi alpha-globin 5' MAR

<400> 7

ctgcagacct aacctgtcac

20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for CHO DHFR intron MAR

<400> 8
tatacgtgaa tagtttttct 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for CHO DHFR intron MAR

<400> 9
gagttggaac tgagaagttc 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human HPRT intron MAR

<400> 10
aagcttggtc aagaatgctg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human HPRT intron MAR

<400> 11
gctgggcgctg gtgggtgcctg 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human CSP-B gene flanking SAR element

<400> 12
ggatcccatt ctccttgatg 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human CSP-B gene flanking SAR element

<400> 13
gaattcaaac aactcaatag 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human interferon-beta gene flanking SAR element

<400> 14
gaattcagca aggtcgccac 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer for human interferon-beta gene flanking SAR element

<400> 15
ttgtatcaac tttctacaat 20

<210> 16
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> sense primer for constructing pSV-beta-gal/ver1 vector

<400> 16
gcactagtcc cgggcccatg attacgaatt c 31

<210> 17

<211> 25
<212> DNA
<213> Artificial Sequence

<220>

<223> sense primer for constructing pSV-beta-gal/ver1 vector

<400> 17

gtgccagctt gcatgcctgc aggtc

25

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 18

agggcccgtt gacattgatt attg

24

<210> 19

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 19

aagcttgcta gcgagctctg cttatataga cctccc

36

<210> 20

<211> 26

<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 20
cctaggtaat acgactcact ataggg

26

<210> 21
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 21
gtcgacacgc gtgtttaaac gggccctcta g

31

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR01/02178

A. CLASSIFICATION OF SUBJECT MATTER**IPC7 C12N 15/85**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C12N 15/85

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NCBI pubmed, KIPO NPS database

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J Virol 1998 May;72(5):3720-8	1-5, 6-9, 10-11
X	J Virol 2000 Mar;74(6):2671-8	1-5, 6-9, 10-11
A	Hum Gene Ther 1999 May 20;10(8):1389-99	1-5, 6-9, 10-11
A	Acta Biochim Pol 1995;42(2):171-6	1-5, 6-9, 10-11
A	Biochemistry 1991 Feb 5;30(5):1264-70	1-5, 6-9, 10-11
A	Biochemistry 1990 Aug 14;29(32):7475-85	1-5, 6-9, 10-11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 APRIL 2002 (24.04.2002)

Date of mailing of the international search report

25 APRIL 2002 (25.04.2002)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, 920 Dunsan-dong, Seo-gu,
Daejeon Metropolitan City 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LIM, Hea Joon

Telephone No. 82-42-481-5590



